Guggenheim Raises Price Target for Assembly Biosciences to $39 on Strong Clinical Data

Investment firm Guggenheim has issued a bullish update on Assembly Biosciences, increasing its price target for the biopharmaceutical company to $39 per share. This optimistic reassessment follows the release of compelling interim data from a Phase 1b clinical trial for the company’s investigational herpes treatment, ABI-5366.

The analyst’s research note highlighted particularly strong results from the study. The drug candidate demonstrated a remarkable 94 percent reduction in HSV-2 viral load, accompanied by a corresponding decline in genital lesions. These outcomes significantly surpassed the trial’s predefined objectives, indicating substantial therapeutic potential.

This latest clinical success builds upon a series of positive developments for Assembly Biosciences in recent weeks. The company’s second-quarter financial performance exceeded analyst forecasts, with a reported loss per share of $1.33, notably better than the anticipated $1.73 loss. Furthermore, quarterly revenue reached $9.63 million, substantially outpacing projections of $5.30 million. The company’s financial position was also strengthened through an equity financing round that raised approximately $175 million.

Should investors sell immediately? Or is it worth buying Assembly Biosciences?

A key strategic partnership continues to provide a solid foundation for the company’s operations. Gilead Sciences, a collaborative partner, participated significantly in the recent financing by acquiring nearly 2.3 million shares. As of June 30, 2025, Assembly Biosciences reported cash and equivalents of $75.0 million, which management believes provides sufficient runway to fund operations through mid-2026.

The investment community is now looking toward several upcoming catalysts that could further influence the company’s valuation. Proof-of-concept data for both herpes candidates, ABI-5366 and ABI-1179, are expected by fall 2025. Additionally, an abstract concerning the hepatitis delta virus candidate ABI-6250 has been accepted for presentation at the upcoming International HBV Meeting.

Future stock performance is likely to be heavily dependent on these forthcoming clinical readouts and scientific presentations. Guggenheim’s revised price target reflects growing confidence in the depth and potential of Assembly Biosciences’ developmental pipeline.